250 related articles for article (PubMed ID: 31236688)
21. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice.
Fickert P; Pollheimer MJ; Silbert D; Moustafa T; Halilbasic E; Krones E; Durchschein F; Thüringer A; Zollner G; Denk H; Trauner M
J Hepatol; 2013 Jun; 58(6):1201-8. PubMed ID: 23369794
[TBL] [Abstract][Full Text] [Related]
22. Toxicity of ethanol and acetaldehyde in hepatocytes treated with ursodeoxycholic or tauroursodeoxycholic acid.
Henzel K; Thorborg C; Hofmann M; Zimmer G; Leuschner U
Biochim Biophys Acta; 2004 Feb; 1644(1):37-45. PubMed ID: 14741743
[TBL] [Abstract][Full Text] [Related]
23. Perinatal exposure to UDCA prevents neonatal cholestasis in Cyp2c70
de Vries HD; Palmiotti A; Li R; Hovingh MV; Mulder NL; Koehorst M; Bloks VW; van Zutphen T; Kuipers F; de Boer JF
Pediatr Res; 2023 May; 93(6):1582-1590. PubMed ID: 36151295
[TBL] [Abstract][Full Text] [Related]
24. Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases.
Festi D; Montagnani M; Azzaroli F; Lodato F; Mazzella G; Roda A; Di Biase AR; Roda E; Simoni P; Colecchia A
Curr Clin Pharmacol; 2007 May; 2(2):155-77. PubMed ID: 18690863
[TBL] [Abstract][Full Text] [Related]
25. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases.
Trauner M; Graziadei IW
Aliment Pharmacol Ther; 1999 Aug; 13(8):979-96. PubMed ID: 10468672
[TBL] [Abstract][Full Text] [Related]
26. Tauroursodeoxycholic acid protects cholestasis in rat reperfused livers: its roles in hepatic calcium mobilization.
Ono T; Imai K; Kohno H; Uchida M; Takemoto Y; Dhar DK; Nagasue N
Dig Dis Sci; 1998 Oct; 43(10):2201-10. PubMed ID: 9790455
[TBL] [Abstract][Full Text] [Related]
27. Hepatoprotection in ethinylestradiol-treated rats is provided by tauroursodeoxycholic acid, but not by ursodeoxycholic acid.
Azer SA; Canfield PJ; Stacey NH
J Gastroenterol Hepatol; 1995; 10(3):261-9. PubMed ID: 7548801
[TBL] [Abstract][Full Text] [Related]
28. Rationale for therapy with ursodeoxycholic acid in patients with cholestatic liver disease.
van Erpecum KJ; van de Meeberg PC; van Berge Henegouwen GP
Neth J Med; 1993 Dec; 43(5-6):233-8. PubMed ID: 8107930
[TBL] [Abstract][Full Text] [Related]
29. Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis.
Beraza N; Ofner-Ziegenfuss L; Ehedego H; Boekschoten M; Bischoff SC; Mueller M; Trauner M; Trautwein C
Gut; 2011 Mar; 60(3):387-96. PubMed ID: 21115542
[TBL] [Abstract][Full Text] [Related]
30. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
31. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.
Munoz-Garrido P; Marin JJ; Perugorria MJ; Urribarri AD; Erice O; Sáez E; Úriz M; Sarvide S; Portu A; Concepcion AR; Romero MR; Monte MJ; Santos-Laso Á; Hijona E; Jimenez-Agüero R; Marzioni M; Beuers U; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Drenth JP; Banales JM
J Hepatol; 2015 Oct; 63(4):952-61. PubMed ID: 26044126
[TBL] [Abstract][Full Text] [Related]
32. Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders.
Trauner M; Halilbasic E; Claudel T; Steinacher D; Fuchs C; Moustafa T; Pollheimer M; Krones E; Kienbacher C; Traussnigg S; Kazemi-Shirazi L; Munda P; Hofer H; Fickert P; Paumgartner G
Dig Dis; 2015; 33(3):433-9. PubMed ID: 26045280
[TBL] [Abstract][Full Text] [Related]
33. Differential regulation of cyclin D1 and cell death by bile acids in primary rat hepatocytes.
Castro RE; Amaral JD; Solá S; Kren BT; Steer CJ; Rodrigues CM
Am J Physiol Gastrointest Liver Physiol; 2007 Jul; 293(1):G327-34. PubMed ID: 17431217
[TBL] [Abstract][Full Text] [Related]
34. Review: The bile acids urso- and tauroursodeoxycholic acid as neuroprotective therapies in retinal disease.
Daruich A; Picard E; Boatright JH; Behar-Cohen F
Mol Vis; 2019; 25():610-624. PubMed ID: 31700226
[TBL] [Abstract][Full Text] [Related]
35. Modulation of rat hepatocyte proliferation by bile salts: in vitro and in vivo studies.
Barone M; Francavilla A; Polimeno L; Ierardi E; Romanelli D; Berloco P; Di Leo A; Panella C
Hepatology; 1996 May; 23(5):1159-66. PubMed ID: 8621149
[TBL] [Abstract][Full Text] [Related]
36. Apoptosis and modulation of cell cycle control by bile acids in human leukemia T cells.
Fimognari C; Lenzi M; Cantelli-Forti G; Hrelia P
Ann N Y Acad Sci; 2009 Aug; 1171():264-9. PubMed ID: 19723064
[TBL] [Abstract][Full Text] [Related]
37. 24-Norursodeoxycholic acid reshapes immunometabolism in CD8
Zhu C; Boucheron N; Müller AC; Májek P; Claudel T; Halilbasic E; Baazim H; Lercher A; Viczenczova C; Hainberger D; Preglej T; Sandner L; Alteneder M; Gülich AF; Khan M; Hamminger P; Remetic J; Ohradanova-Repic A; Schatzlmaier P; Donner C; Fuchs CD; Stojakovic T; Scharnagl H; Sakaguchi S; Weichhart T; Bergthaler A; Stockinger H; Ellmeier W; Trauner M
J Hepatol; 2021 Nov; 75(5):1164-1176. PubMed ID: 34242699
[TBL] [Abstract][Full Text] [Related]
38. Long-term effect of treating pregnant rats with ursodeoxycholic acid on the congenital impairment of bile secretion induced in the pups by maternal cholestasis.
Macias RI; Serrano MA; Monte MJ; Jimenez S; Hernandez B; Marin JJ
J Pharmacol Exp Ther; 2005 Feb; 312(2):751-8. PubMed ID: 15452192
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease.
Steinacher D; Claudel T; Trauner M
Dig Dis; 2017; 35(3):282-287. PubMed ID: 28249257
[TBL] [Abstract][Full Text] [Related]
40. [Ursodeoxycholic acid in the treatment of cholestatic liver diseases].
Arrese M; Accatino L
Rev Med Chil; 1993 Apr; 121(4):439-46. PubMed ID: 8272619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
